Xolair 300 MG/2 ML syringe 2ML

Ended Awarded

Contract number
SPE2DR26FRST8
Awardee
Awarding agency
Obligated
$4,761

Award facts

Contract value 100% obligated
$4,761.09 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
424210 Drugs and Druggists' Sundries Merchant Wholesalers
PSC
6505 Drugs And Biologicals
Set-aside
No set-aside
Competition
Full and Open Competition Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Park Ridge, IL 60068, USA

Award details come from SAM.gov/FPDS.

About this award

The Defense Logistics Agency issued a $4,761.09 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, on July 17, 2026, for XOLAIR 300 mg/2 ml syringes under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V).

DMS Pharmaceutical holds a single-award indefinite delivery contract (SPE2DX) under PPV-G GEN V with a $499.999 billion ceiling running through December 31, 2036. The underlying IDC is structured with a 30-month base period and three 30-month option periods. Place of performance is Park Ridge, Illinois. The ultimate completion date for this delivery order is August 7, 2026. Pricing is firm fixed price.

Quick answers

Who was awarded contract SPE2DR26FRST8?

SPE2DR26FRST8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on July 17, 2026.

How much is contract SPE2DR26FRST8 worth?

The government has obligated $4,761 on SPE2DR26FRST8.

Is contract SPE2DR26FRST8 an order under another contract?

Yes. SPE2DR26FRST8 is a delivery order under SPE2DR25D9238, an indefinite delivery contract.

Was contract SPE2DR26FRST8 competed?

The extent of competition for SPE2DR26FRST8 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award